AbbVie’s $10.9B APGE buyout sparks sympathy surge in peer JBIO
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $282.00K | $96.00K | $68.00K | $15.00K | $1.00K |
| Gross Profit | $-282.00K | $-96.00K | $-68.00K | $-15.00K | $-1.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $74.31M | $81.31M | $53.17M | $23.01M | $8.89M |
| Operating Income | $-74.60M | $-81.41M | $-53.24M | $-23.02M | $-8.89M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-69.63M | $-75.52M | $-51.51M | $-22.96M | $-9.61M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-85.26 | $-100.38 | $-73.67 | $-32.96 | $-14.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |